Gene therapy is rapidly moving from the laboratory to the clinic, with its success hinging on how therapeutic genes can be safely and efficiently delivered into target cells.

The continuous evolution of vector technologies—from classical AAV and lentivirus to emerging non-viral and engineered vectors—has steadily expanded the scope and effectiveness of gene therapies.

In this process, the global pharmaceutical distributor DengYueMed not only tracks research and technological advances but also promotes the global accessibility of innovative therapies, ensuring that laboratory findings reach the clinic more quickly through efficient supply chains and cold-chain logistics.

AAV Vectors: A Safe and Precise Classic Choice

Adeno-associated viruses (AAV) have long been a key tool for gene delivery due to their low immunogenicity and tissue specificity. They can achieve long-term gene expression in non-dividing cells, making them particularly suitable for the nervous system, heart, and liver.

Although the vector has a limited packaging capacity of approximately 4.7 kb, researchers have gradually addressed this limitation through dual-vector strategies or gene compression designs.

Additionally, different AAV serotypes (e.g., AAV8, AAV9) can be selected to optimize tissue tropism and therapeutic precision.

Clinically, AAV vectors have already achieved significant milestones. Luxturna® restores vision in patients with RPE65 mutations through a single intraocular injection, while Zolgensma® significantly slows disease progression in infants with spinal muscular atrophy (SMA).

The advantages of AAV include precise delivery and long-term expression, though pre-existing antibodies may affect treatment efficacy.

● Advantages: Low immunogenicity, tissue specificity, long-term expression

● Limitations: Small packaging capacity, potential interference from pre-existing antibodies

diagram of AAV components

Lentiviral Vectors: Efficient Tools for Complex Cellular Environments

Lentiviral vectors integrate into the host genome, enabling long-term stable expression, which makes them highly suitable for dividing cells and stem cell modifications.

In CAR-T therapy, lentiviruses can stably introduce chimeric antigen receptors into T cells, allowing the modified cells to persist in the body and continuously recognize and attack tumor cells. Their relatively large capacity also allows delivery of longer genes or multiple regulatory elements, supporting complex therapeutic strategies.

However, integration carries potential risks, such as insertional mutagenesis, which could affect genomic stability.

Researchers mitigate these risks through safe-harbor targeting, site-directed integration, and in vitro selection, and typically perform cell modifications outside the patient before reinfusion, minimizing interference from in vivo immune responses.

Clinically, lentiviral vectors are widely applied in hematological disorders and immunotherapies, including CAR-T therapy for acute lymphoblastic leukemia (ALL), multiple myeloma, and stem cell gene therapies for β-thalassemia and sickle cell disease. Recent advances, such as self-inactivating lentiviruses and optimized integration sites, further enhance safety and long-term expression stability.

● Advantages: Long-term stable expression, large capacity, suitable for ex vivo cell modification

● Limitations: Risk of insertional mutagenesis, limited in vivo delivery, sensitive to immune environment

schematic structure of the lentiviral vector

Novel Vectors: Exploring Beyond Traditional Boundaries

Novel vectors are breaking the limitations of traditional viral vectors in terms of payload and immunogenicity, offering new possibilities for gene delivery. Non-viral technologies, such as lipid nanoparticles (LNPs) and polymer-based vectors, avoid virus-associated safety issues and can achieve tissue targeting through surface modifications.

Engineered viruses and hybrid systems use capsid engineering and sequence optimization to improve payload capacity and targeting precision, providing effective platforms for in vivo gene editing.

Preclinical and early clinical studies indicate that these novel vectors have potential in treating heart, liver, and central nervous system diseases. For example, LNP-mediated delivery of CRISPR/Cas9 systems to the liver allows efficient gene editing with minimal immunogenicity.

In rare diseases, such as congenital metabolic disorders and inherited cardiomyopathies, non-viral vectors have entered Phase I/II clinical trials, demonstrating favorable safety profiles and measurable gene correction.

Future developments include multi-gene vector designs, enhanced tissue specificity, and controllable expression systems, making gene therapies safer, more precise, and suitable for complex disease interventions.

● Advantages: Flexible payload, high safety, multi-tissue targeting, suitable for in vivo gene editing

● Limitations: Limited clinical experience, many technologies still in early stages, long-term efficacy requires further validation

Technology Integration and Future Trends

Looking ahead, gene delivery is likely to rely more on multi-vector combination strategies to overcome the limitations of individual vectors.

AAV can be used for precise in vivo delivery, achieving long-term expression in specific tissues such as the central nervous system or heart; LNPs provide auxiliary modifications, controllable expression, and rapid degradation; lentiviruses are suitable for ex vivo stem cell modification, enabling modified cells to persist and exert therapeutic effects.

This synergistic approach allows for a balance between precise targeting, controlled release, and long-term efficacy in complex diseases.

At both clinical and industrial levels, integrating multiple technologies poses several challenges:

● Pharmacokinetics and immune response differences: Different vectors vary in distribution, clearance, and immune activation, requiring careful dose and administration design.

● Production and quality control complexity: Multi-vector combinations increase GMP manufacturing difficulty, necessitating batch consistency and strict quality testing.

● Interdisciplinary integration: From vector design to clinical application, molecular biology, drug formulation, clinical medicine, and logistics must work together to ensure safety, efficacy, and accessibility.

● Clinical trial and data standardization challenges: Multi-center studies and long-term efficacy evaluation require careful trial design and standardized data collection.

The deep integration of technology and industry will determine whether gene therapies can achieve long-term, controllable, and safe outcomes across a wider range of diseases.

Conclusion: From the Laboratory to Global Patients

From AAV and lentiviruses to novel non-viral and engineered vectors, gene delivery technology is advancing toward safer, more efficient, and more precise therapies. Each technological breakthrough brings new hope to patients.

Through its global supply network, DengYueMed bridges the gap between innovation and accessibility, helping cutting-edge gene therapies reach clinical practice worldwide.

As technology and industry continue to synergize, gene therapy is expected to cover a broader range of chronic and immune-related diseases, achieving widespread societal impact and laying the foundation for future precision medicine.